Holen Sie sich die Stockscreener-App
193.67
0.26%
0.51
Handel nachbörslich:
193.67
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$193.16
Offen:
$193
24-Stunden-Volumen:
642.85K
Relative Volume:
0.73
Marktkapitalisierung:
$21.44B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
21.36
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
-0.16%
1M Leistung:
+0.52%
6M Leistung:
+6.06%
1J Leistung:
+11.57%
1-Tages-Spanne:
$192.38
$195.21
1-Wochen-Bereich:
$191.01
$197.38
52-Wochen-Spanne:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
193.67 | 21.38B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
473.95 | 179.15B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
178.08 | 124.65B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.73 | 43.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.40 | 38.14B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
379.77 | 36.52B | 3.77B | 449.25M | 240.68M | 7.8556 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics Insider Sold Shares Worth $1,941,400, According to a Recent SEC Filing - marketscreener.com
Insider Sell: J. Davis Sells 10,000 Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics CEO sells $1.94 million in company stock By Investing.com - Investing.com South Africa
Quest Diagnostics CEO sells $1.94 million in company stock - Investing.com
Quest Diagnostics (DGX) CEO sells 10,000 shares in Rule 10b5-1 trade - Stock Titan
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Affiliate sale notice — DGX (DGX) to sell 10,000 shares - Stock Titan
DGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year? - Yahoo Finance
Quest Diagnostics Stock: Analyst Estimates & Ratings - Yahoo Finance
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting - Investing.com India
Quest Diagnostics 8-K SEC Filing May 2026: Shareholder Vote Results and Company Information - Minichart
Quest Diagnostics (DGX) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Quest Diagnostics (DGX) director granted 1,142 restricted stock units in Form 4 filing - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 RSUs - Stock Titan
Quest Diagnostics (DGX) director receives 1,142-share restricted stock unit grant - Stock Titan
Quest Diagnostics (DGX) director gets 1,142-share restricted stock unit award - Stock Titan
Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award - Stock Titan
Director at Quest Diagnostics (DGX) awarded 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 stock units - Stock Titan
Quest Diagnostics (DGX) director receives 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (DGX) receives 1,142 share units - Stock Titan
Quest Diagnostics (NYSE: DGX) details 2026 shareholder votes on board, pay and auditor - Stock Titan
Why is Quest Diagnostics (DGX) down 5% since last earnings report? - MSN
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report? - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Keeps Quarterly Dividend at $0.86 a Share, Payable July 22 to Holders of Record July 8 - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend - Barchart.com
Guardant Health’s Shield Blood-Based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Nevada Business Magazine
Is This the Right Time to Hold DGX Stock in Your Portfolio? - TradingView
$0.86 a share: Quest Diagnostics dividend hits investors in July - Stock Titan
Quest Diagnostics Incorporated announces Quarterly dividend, payable on July 22, 2026 - marketscreener.com
Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating - Moomoo
Quest Diagnostics (NYSE:DGX): A Solid Dividend Play Backed by Strong Profitability and Financial Health - ChartMill
International Assets Investment Management LLC Purchases New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Q2 EPS Estimates for Quest Diagnostics Cut by Zacks Research - MarketBeat
173,262 Shares in Quest Diagnostics Incorporated $DGX Bought by Conning Inc. - MarketBeat
How The Investment Narrative For Quest Diagnostics (DGX) Is Shifting With New Valuation Work - Yahoo Finance
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics Incorporated $DGX Shares Acquired by Ethic Inc. - MarketBeat
Truist Financial Corp Cuts Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Swedbank AB Increases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Generali Asset Management SPA SGR Purchases 8,924 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics (NYSE: DGX) sells $500M in 5.000% senior notes due 2036 - Stock Titan
Quest Diagnostics Incorporated Issues $500,000,000 of 5.000% Senior Notes Due June 30, 2036 - marketscreener.com
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
5.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):